Table 1 Patient characteristics
From: Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
IIPs | Non-ILD | ||||
|---|---|---|---|---|---|
UIP + non- UIP IIPs | UIP | Non-UIP IIPs | |||
Number of patients | 25 | 12 | 13 | 88 | |
Age (year) | Median (range) | 69 (58–81) | 71 (58–80) | 68 (60–81) | 70 (35–92) |
Gender | Male (%) | 23 (92.0) | 12 (100) | 11 (84.6) | 41 (46.6) |
Smoking History | Yes (%) | 24 (96.0) | 12 (100) | 12 (92.3) | 49 (55.7) |
Performance status | 0-1 (%) | 21 (84.0) | 10 (83.3) | 11 6) | 80 (92.0) |
Histology | Adenocarcinoma (%) | 22 (88.0) | 10 (83.3) | 12 (92.3) | 83 (94.3) |
Stage | IIIB + IV (%) | 19 (76.0) | 10 (83.3) | 9 (69.2) | 73 (82.9) |
Line | 1/2/3 | 5/10/10 | 2/4/6 | 3/6/4 | 13/44/31 |
EGFR mutation | Sensitive (%) | 3 (12.0) | 1 (8.3) | 2 (15.3) | 28 (31.8) |